Thematics Asset Management Boosts Holdings in Exact Sciences Corporation $EXAS

Thematics Asset Management grew its position in Exact Sciences Corporation (NASDAQ:EXAS) by 9.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,253 shares of the medical research company’s stock after acquiring an additional 6,446 shares during the quarter. Thematics Asset Management’s holdings in Exact Sciences were worth $3,898,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in EXAS. Integrated Wealth Concepts LLC bought a new stake in shares of Exact Sciences during the 1st quarter worth approximately $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Exact Sciences by 11.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company’s stock worth $921,000 after purchasing an additional 2,231 shares during the period. Great Lakes Advisors LLC lifted its position in shares of Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $215,000 after purchasing an additional 178 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Exact Sciences by 12.6% during the first quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company’s stock valued at $933,000 after purchasing an additional 2,413 shares during the period. Finally, Allworth Financial LP boosted its stake in shares of Exact Sciences by 130.1% during the second quarter. Allworth Financial LP now owns 6,871 shares of the medical research company’s stock valued at $365,000 after purchasing an additional 3,885 shares during the period. Institutional investors own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Leerink Partners lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Citigroup lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, November 20th. Craig Hallum downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price target for the company. in a research note on Friday, November 21st. TD Cowen lowered Exact Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, William Blair cut Exact Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 20th. Twenty-one research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $92.13.

Exact Sciences Trading Up 0.3%

NASDAQ:EXAS opened at $103.57 on Friday. The firm has a 50-day simple moving average of $102.83 and a 200-day simple moving average of $83.60. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $103.75. The firm has a market cap of $19.77 billion, a P/E ratio of -94.15, a P/E/G ratio of 2.35 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.06) EPS. Equities analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.